Table 4.
The combined modes of anti-PD-1 and CCRT in the treatment of LACC.
| Three modes of anti-PD-1 plus CCRT | Anti-PD-1 | Administration Dose |
Maintenance dose and time | Phase | Sample | ORR | Clinical identifier |
Ref. |
|---|---|---|---|---|---|---|---|---|
|
Nivolumab | 240 mg/kg q2w | 240 mg/kg q2w (52 weeks) |
I | 15 (cohort B) |
– | GOTIC-018 NCT03298893 |
(51) |
|
Nivolumab | 240 mg/kg q2w | 240 mg/kg q2w (52 weeks) |
I | 15 (cohort A) |
– | GOTIC-018 NCT03298893 |
(51) |
| Nivolumab | 240 mg/kg q2w | 240 mg/kg q2w (5 months) |
I | 16 | 93.8% | NiCOL NCT03298893 |
(52) | |
| Toripalimab | 240 mg q3w | 240 mg q6w (reach 1 year) |
II | 96 | ≈ 80% | NCT05084677 | (53) | |
| Pembrolizumab | 200 mg q3w | 400 mg q6w (15 cycles) |
III | 980 | – | KEYNOTE-A18, NCT04221945 | – | |
| Camrelizumab | – | q2w until PD |
II | 92 | – | NCT05311566 | – | |
|
Toripalimab | 240 mg days 1, 22, 43 |
– | I/II | 22 | 100% | NCT04368273 | (54) |
| Cadonilimab | q3w | – | III | 636 | – | NCT05235516) | – |
ORR, objective response rate; CCRT, concurrent chemoradiotherapy; PD, progressive disease.